Related Experiment Video
Updated: May 20, 2026
07:20
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Biosignatures: comparative effectiveness research in biomarker clinical studies.
Jur-Shan Cheng1, David Bin-Shiun Wu, Yu Wen Wen
1Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, Taiwan.
Summary
Comparative Effectiveness Research (CER) improves healthcare efficiency by comparing treatment benefits, harms, and costs. A new Taiwanese Biosignatures project applies CER principles to biomarker discovery for early disease detection and treatment prediction.
Area of Science:
- Health Services Research
- Biomarker Discovery
- Translational Medicine
Background:
- Rising healthcare costs necessitate evidence-based clinical decisions.
- Comparative Effectiveness Research (CER) was developed in the US to evaluate healthcare interventions.
- CER synthesizes evidence on the relative benefits, harms, and costs of different medical alternatives.
Purpose of the Study:
- To introduce a novel Biosignatures project in Taiwan inspired by CER principles.
- To leverage discovered biomarker panels for early disease detection.
- To utilize biomarkers for predicting treatment effectiveness.
Main Methods:
- Generating and synthesizing evidence from head-to-head comparisons of interventions.
- Applying CER methodologies to biomarker discovery and validation.
- Developing biomarker panels for clinical application.
Main Results:
- CER facilitates identification of optimal interventions for specific patient populations.
- The Biosignatures project aims to enhance diagnostic and prognostic capabilities.
- Biomarker panels show potential for improving healthcare system efficiency.
Conclusions:
- CER is crucial for optimizing healthcare efficiency and patient outcomes.
- The Taiwanese Biosignatures project extends CER concepts to biomarker-driven healthcare.
- Biomarker discovery holds promise for personalized medicine and early disease intervention.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...